期刊
ENDOCRINE
卷 52, 期 3, 页码 414-426出版社
SPRINGER
DOI: 10.1007/s12020-016-0888-7
关键词
Osteoporosis; Sclerostin; Cathepsin K; Pycnodystostosis; Van Buchem disease; Sclerosteosis
资金
- Amgen
- Axsome
- Merck Co
- Novartis
- UCB
During the past 15 years there has been an expansion of our knowledge of the cellular and molecular mechanisms regulating bone remodeling that identified new signaling pathways fundamental for bone renewal as well as previously unknown interactions between bone cells. Central for these developments have been studies of rare bone disorders. These findings, in turn, have led to new treatment paradigms for osteoporosis some of which are at late stages of clinical development. In this article, we review three rare skeletal disorders with case descriptions, pycnodysostosis and the craniotubular hyperostoses sclerosteosis and van Buchem disease that led to the development of cathepsin K and sclerostin inhibitors, respectively, for the treatment of osteoporosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据